Stockreport
BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology [Reuters]
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
PDF
BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology | Reuters Reuters Staff 1 Min Read April 16 (Reuters) - XBiotech Inc: * XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY * XBIOTECH INC - CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved.
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | XBIT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
XBIT alerts
XBIT alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XBIT alerts
High impacting XBIOTECH INC COMMON news events
Weekly update
A roundup of the hottest topics
XBIT
NEWS
NEWS
- XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa[GlobeNewswire]
- XBiotech Announces Addition of Top Dermatologist and Researcher Dr. Alice Gottlieb to its Team[GlobeNewswire]
- XBiotech's bermekimab shows positive effect dermatitis pilot study; shares up 28% premarket [Seeking Alpha][Seeking Alpha]
- XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis[GlobeNewswire]
- XBiotech tries to right the ship, shares up 24% [Seeking Alpha][Seeking Alpha]
- More
XBIT
SEC Filings
SEC Filings
- 9/18/18 - Form 4
- 9/11/18 - Form 4
- 9/6/18 - Form 4
- XBIT's page on the SEC website
- More